MedTrace Logo

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

NCT06585462 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-13

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Conditions

Interventions

DRUG

AMG 513

AMG 513 will be administered by SC or IV injection.

DRUG

Placebo

Placebo will be administered by SC or IV injection.

DRUG

AMG 513

AMG 513 will be administered by SC injection.

DRUG

Placebo

Placebo will be administered by SC injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-09
Primary Completion
2026-10-01
Completion
2026-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06585462 on ClinicalTrials.gov